Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. Horn, L., Infante, J. R., Blumenschein, G. R., Wakelee, H. A., Arkenau, H., Dukart, G., Liang, C., Harrow, K., Gibbons, J., Lovly, C., Pao, W. AMER SOC CLINICAL ONCOLOGY. 2014
View details for Web of Science ID 000358613204095